Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  pembrolizumab
Find trials that include:  Any drugs shown
Results 1-25 of 66 for your search:
Start Over
Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-024, NCI-2014-01865, 142728, 2014-000323-25, NCT02142738
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-040, NCI-2014-02662, 2014-001749-26, NCT02252042
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-045, NCI-2014-02598, 152903, 2014-002009-40, NCT02256436
Pembrolizumab (MK-3475) With or Without Talimogene Laherparepvec in Unresected Melanoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 20110265, NCI-2015-00094, 2014-000185-22, NCT02263508
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-048, NCI-2015-00270, 2014-003698-41, NCT02358031
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-054, NCI-2015-01366, 1325-MG, 2014-004944-37, NCT02362594
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 3475-021, NCI-2014-00482, NCT02039674
Pembrolizumab and Combination Chemotherapy in Treating Patients with Advanced Colorectal, Gastroesophageal, Pancreatic, or Biliary Tract Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HCI76239, NCI-2015-00123, 3475-085, 76239, MK-3475 GI, NCT02268825
MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201501072, NCI-2015-00119, 14-x326, NCT02311582
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)
Phase: Phase II, Phase I
Type: Treatment
Age: 6 months to less than 18 years
Trial IDs: 3475-051, NCI-2015-00528, 2014-002950-38, NCT02332668
ACP-196 in Combination With Pembrolizumab, for Treatment of B-Cell Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-LY-005, NCI-2015-01019, NCT02362035
Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: HCRN GU14-188, NCI-2015-01257, NCT02365766
Carboplatin and Nab-paclitaxel with Pembrolizumab in Treating Patients with Stage IIIB or IV Non-small Cell Lung Cancer That is Unable To Be Removed with Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 14L01, NCI-2015-00617, HCRN LUN13-175, LUN13-175, NCI-2015-00449, NCT02382406
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SNDX-275-0601, NCI-2015-01180, NCT02437136
Pembrolizumab in Treating Patients with Metastatic or Locally Advanced Microsatellite Unstable Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J1365, NCI-2013-02436, CIR00001187, MK-3475-016, NA_00085756, NA_00085756 / CIR00007001, NCT01876511
Pembrolizumab in Treating Patients with Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CITN-10, NCI-2014-00709, NCT02243579
Pembrolizumab and Azacitidine in Treating Patients with Metastatic Colorectal Cancer That Has Not Responded to Chemotherapy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 14-118, NCI-2014-02417, NCT02260440
Pembrolizumab in Treating Patients with Advanced Merkel Cell Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CITN-09, NCI-2014-00848, MK-3475, NCT02267603
Pembrolizumab in Treating Patients with Locoregionally Advanced Head and Neck Cancer That Can Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201412118, NCI-2014-02626, 14-x330, NCT02296684
Start Over